BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/15/2016 9:49:00 AM | Browse: 1683 | Download: 2415
Publication Name World Journal of Hepatology
Manuscript ID 22537
Country France
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Ribavirin: Past, present and future
Manuscript Source Invited Manuscript
All Author List Véronique Loustaud-Ratti, Marilyne Debette-Gratien, Jérémie Jacques, Sophie Alain, Pierre Marquet, Denis Sautereau, Annick Rousseau and Paul Carrier
Funding Agency and Grant Number
Corresponding Author Véronique Loustaud-Ratti, Professor, Fédération Hépatologie, Service d’Hépato-gastroentérologie, CHU Limoges, 2 Avenue Martin Luther King, 87042 Limoges, France. veronique.loustaud-ratti@unilim.fr
Key Words Ribavirin; Hepatitis C; Peginterferon; Direct acting antiviral agents
Core Tip Ribavirin plays a crucial role when asso-ciated with peginterferon, preventing relapses and breakthroughs and doubling the support vector regre-ssion rate. Its antiviral effect is weak and ribavirin could enhance the response of interferon-stimulated genes in the combination. Ribavirin is still useful in the era of approved new direct acting antiviral agents (DAAs), in order to shorter treatment duration in genotype 1 or 4 cirrhotic patients, in all options available for genotype 3 cirrhotic patients, and as the only drug associated with sofosbuvir in genotype 2. Preliminary data with interferon-free second generation DAAs combinations without ribavirin suggest that future of the drug is jeopardized.
Publish Date 2016-01-15 09:49
Citation Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-130
URL http://www.wjgnet.com/1948-5182/full/v8/i2/123.htm
DOI http://dx.doi.org/10.4254/wjh.v8.i2.123
Full Article (PDF) WJH-8-123.pdf
Full Article (Word) WJH-8-123.doc